Bellus Health Incis A Clinical Stage Biopharmaceutical Company Based In Canadaestablished In 2012The Company Focuses On Developing Innovative Therapeutics For Chronic Cough And Related Hypersensitization Disordersits Lead Productcamlipixantblu 5937 Is A Selective Antagonist Of The P2X3 Receptor And Is Currently Undergoing Evaluation In The Calm Phase Iii Clinical Development Program For Refractory Chronic Cough In Adults In April 2023Bellus Health Was Acquired By Gsk For Approximately $2 0 Billiona Move That Underscores The Potential Of Camlipixant And Enhances Gsk S Specialty Medicines And Respiratory Pipelinethis Acquisition Provides Bellus Health With Significant Resources To Advance The Development And Commercialization Of Its Therapeutic Products
